Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: April 13, 2026
Context: This filing reports on the progress of a share repurchase programme initiated on February 4, 2026. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries.
Key Financial Metrics
This filing focuses on capital allocation activities rather than operational financial performance. Key metrics include:
- Share Repurchase Programme Total: Up to DKK 15 billion over a 12-month period starting February 4, 2026.
- Current Period Repurchases (Feb 4 - Apr 10, 2026): DKK 2,835,176,799.
- Shares Repurchased: 11,007,992 B shares.
- Average Purchase Price: DKK 257.56 per B share.
- Treasury Shares Held: 28,397,791 B shares (0.6% of total share capital).
- Total Share Capital: 4,465,000,000 shares (including treasury shares).
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the previous announcement on April 7, 2026, the company executed four additional transactions:
- April 8: 260,000 shares at DKK 242.28 (Value: DKK 62,993,029).
- April 9: 260,000 shares at DKK 236.25 (Value: DKK 61,424,153).
- April 10: 260,000 shares at DKK 242.79 (Value: DKK 63,126,047).
- Cumulative Impact: Total repurchased value increased from DKK 2,586,404,548 to DKK 2,835,176,799.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total programme limit of DKK 15 billion within the 12-month window beginning February 4, 2026.
Regulatory Context: The programme is executed in accordance with Article 5 of Regulation No 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (Safe Harbour Rules).
Risks/Contingencies: The filing does not explicitly state new risks or contingencies beyond the standard execution of the buyback programme.
Investor Verification Checklist
- Verify the remaining capacity of the DKK 15 billion repurchase programme (approx. DKK 12.16 billion remaining as of April 10, 2026).
- Confirm the current market price of B shares relative to the average purchase price of DKK 257.56.
- Review the full transaction details on the company website (novonordisk.com) for granular daily data.
- Check subsequent filings for updates on the 12-month programme completion status.